Accessibility Menu
 
Maze Therapeutics logo

Maze Therapeutics

(NASDAQ) MAZE

Current Price$28.86
Market Cap$1.43B
Since IPO (2025)+80%
5 YearN/A
1 Year+177%
1 Month-35%

Maze Therapeutics Financials at a Glance

Market Cap

$1.43B

Revenue (TTM)

$0.00

Net Income (TTM)

$131.12M

EPS (TTM)

$-2.84

P/E Ratio

-10.10

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$28.86

Volume

30,503

Open

$28.22

Previous Close

$28.86

Daily Range

$28.22 - $29.54

52-Week Range

$6.71 - $53.65

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Maze Therapeutics

Industry

Pharmaceuticals

Employees

141

CEO

Jason V. Coloma, PhD, MBA

Headquarters

South San Francisco, CA 94080, US

MAZE Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-48%

Return on Capital

-38%

Return on Assets

-33%

Earnings Yield

-9.90%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.43B

Shares Outstanding

49.71M

Volume

30.50K

Short Interest

0.00%

Avg. Volume

714.03K

Financials (TTM)

Gross Profit

$2.40M

Operating Income

$142.90M

EBITDA

$140.50M

Operating Cash Flow

$111.94M

Capital Expenditure

$794.00K

Free Cash Flow

$112.73M

Cash & ST Invst.

$341.92M

Total Debt

$23.31M

Maze Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$499.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.43B

N/A

Market Cap/Employee

$11.42M

N/A

Employees

125

N/A

Net Income

$34.57M

-16.9%

EBITDA

$37.56M

-29.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$318.61M

+87.2%

Accounts Receivable

$1.50M

N/A

Inventory

$0.00

N/A

Long Term Debt

$18.51M

-15.8%

Short Term Debt

$4.79M

+3.5%

Return on Assets

-33.02%

N/A

Return on Invested Capital

-38.15%

N/A

Free Cash Flow

$27.76M

-20.4%

Operating Cash Flow

$27.73M

-23.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARDXArdelyx, Inc.
$5.94-2.78%
WVEWave Life Sciences Ltd.
$7.28+6.59%
TRVITrevi Therapeutics, Inc.
$11.94+3.11%
NTLAIntellia Therapeutics, Inc.
$13.13-1.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
SKYQSky Quarry
$5.10+1.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.37-0.11%
INTCIntel
$50.38+0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.33+0.00%

Questions About MAZE

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.